Regeneron Pharmaceuticals (REGN) – Analysts’ Recent Ratings Changes

Share on StockTwits

A number of research firms have changed their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

  • 6/11/2019 – Regeneron Pharmaceuticals was given a new $453.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 6/7/2019 – Regeneron Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 6/5/2019 – Regeneron Pharmaceuticals was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 5/23/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Citigroup Inc from $396.00 to $340.00. They now have a “neutral” rating on the stock.
  • 5/23/2019 – Regeneron Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 5/20/2019 – Regeneron Pharmaceuticals is now covered by analysts at Credit Suisse Group AG. They set a “neutral” rating and a $336.00 price target on the stock.
  • 5/13/2019 – Regeneron Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 5/13/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Cantor Fitzgerald from $441.00 to $405.00. They now have a “neutral” rating on the stock.
  • 5/8/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $412.00 to $375.00. They now have a “market perform” rating on the stock.
  • 5/8/2019 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00.
  • 5/8/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Morgan Stanley from $420.00 to $389.00. They now have an “equal weight” rating on the stock.
  • 5/8/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at UBS Group AG from $480.00 to $440.00. They now have a “buy” rating on the stock.
  • 5/7/2019 – Regeneron Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $435.00 price target on the stock.
  • 5/7/2019 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $353.00 price target on the stock.
  • 4/25/2019 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/17/2019 – Regeneron Pharmaceuticals had its price target lowered by analysts at Jefferies Financial Group Inc from $376.00 to $343.00. They now have a “hold” rating on the stock.
  • 4/16/2019 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ:REGN traded up $1.26 during midday trading on Thursday, reaching $307.42. The stock had a trading volume of 653,017 shares, compared to its average volume of 781,372. Regeneron Pharmaceuticals Inc has a 1-year low of $295.27 and a 1-year high of $442.00. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $33.54 billion, a PE ratio of 15.53, a PEG ratio of 1.44 and a beta of 1.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.67 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the completion of the transaction, the director now directly owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The disclosure for this sale can be found here. 11.84% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Joel Isaacson & Co. LLC lifted its holdings in Regeneron Pharmaceuticals by 0.8% during the 1st quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 25 shares during the last quarter. Cornerstone Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 3.7% in the first quarter. Cornerstone Advisors Inc. now owns 842 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 30 shares during the last quarter. Comprehensive Portfolio Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.1% in the first quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 33 shares during the last quarter. Kaizen Advisory LLC raised its stake in shares of Regeneron Pharmaceuticals by 21.2% in the fourth quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 35 shares during the last quarter. Finally, OppenheimerFunds Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2.6% in the first quarter. OppenheimerFunds Inc. now owns 1,465 shares of the biopharmaceutical company’s stock worth $602,000 after acquiring an additional 37 shares during the last quarter. 66.96% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: The Discount Rate – What You Need to Know

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Regeneron Pharmaceuticals  – Analysts’ Recent Ratings Changes
Regeneron Pharmaceuticals – Analysts’ Recent Ratings Changes
Cohen and Steers Global Income Builder Declares Monthly Dividend of $0.06
Cohen and Steers Global Income Builder Declares Monthly Dividend of $0.06
Pundi X Price Up 1.4% Over Last 7 Days
Pundi X Price Up 1.4% Over Last 7 Days
Telaria  Shares Up 6.5%
Telaria Shares Up 6.5%
Zacks: Brokerages Expect Workiva Inc  Will Announce Earnings of -$0.10 Per Share
Zacks: Brokerages Expect Workiva Inc Will Announce Earnings of -$0.10 Per Share
Yocoin  Price Reaches $0.0034 on Top Exchanges
Yocoin Price Reaches $0.0034 on Top Exchanges


© 2006-2019 Ticker Report